Reuters logo
BRIEF-Active Biotech says receives European patent for tasquinimod
January 9, 2017 / 12:05 PM / 8 months ago

BRIEF-Active Biotech says receives European patent for tasquinimod

Jan 9 (Reuters) - Active Biotech AB

* Says the European Patent Office grants patent for tasquinimod for treatment of multiple myeloma

* Says the patent will be granted on February 1, 2017 and has a duration lasting until 2035 Source text for Eikon: Further company coverage: (Stockholm Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below